Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05557045 · ClinicalTrials.gov registry record · Phase 1
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
A Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 332
- Enrollment target
- 14
- Study locations
NCT05557045 is a Phase 1 study of Solid Tumor and Advanced Cancer that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 332 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (51% higher). The trial reports 14 study locations across 9 states.
The verdict
NCT05557045, a Phase 1 study of Solid Tumor and Advanced Cancer, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 332 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Conditions Studied
Interventions
- DRUG JZP815
Study Locations (14)
Texas
- Texas Oncology- Central South - Austin
- University of Texas MD Anderson Cancer Center - Houston
- Texas Oncology- Gulf Coast - The Woodlands
Florida
- Florida Cancer Specialists - Lake Nona - Orlando
- Florida Cancer Specialists - Sarasota - Sarasota
New York
- NYU Langone Health - New York
- Icahn School of Medicine at Mount Sinai - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
- Sidney Kimmel Cancer Center - Philadelphia
Colorado
- SCRI HealthOne - Denver
Illinois
- University of Chicago - Chicago
Oklahoma
- Oklahoma University - Oklahoma City
Tennessee
- Tennessee Oncology - Nashville - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2028-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05557045
The ClinicalTrials.gov registry entry for NCT05557045 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (51% higher). The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which JZP815 is the first listed.
NCT05557045 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Texas, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05557045 about?
NCT05557045 is a clinical study titled "A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815". This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
What is the current status of trial NCT05557045?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 332 participants. The study started on 2022-10-10. Estimated completion is 2028-04-01.
What conditions does trial NCT05557045 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT05557045?
The interventions under investigation include: JZP815 (DRUG).
Who is sponsoring clinical trial NCT05557045?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05557045 being conducted?
This trial has 14 study locations across Colorado, Florida, Illinois, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.